Skip to NavigationSkip to content

Lilly and Boehringer's Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

Published on 15/02/19 at 11:58am

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior to glimepiride in its ability to prolong the amount of time before the first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke in type 2 diabetes patients.

The CAROLINA trial – the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor – examined the efficacy of Trajenta in 6,033 patients with type 2 diabetes in addition to established CV disease or increased CV risk, compared to glimepiride sulphonylurea and standard of care. It provided the longest evaluation ever of a DPP-4 inhibitor in cardiovascular disease, with a median follow-up of over six years.

“Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit,” commented Dr Waheed Jamal, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine at Boehringer Ingelheim. “When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile. With these results, CAROLINA expands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.”

Dr Jeff Emmick, Vice President, Product Development at Lilly Diabetes, added: “These data provide further confidence in the well-established safety and tolerability profile of linagliptin for the treatment of adults with type 2 diabetes. Linagliptin is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes. Boehringer Ingelheim and Lilly look forward to sharing the full results later this year.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches